Beim BRAF-mutierten kolorektales Karzinom ist die Erstlinienterapie nach der Breakwater-Studie jetzt inlabel möglich. Zusätzlich gibt es neue Therapieoptionen für das Plattenepithelkarzinom der Lunge, Mammakarzinom (sowohl triple negativ als auch Östrogenrezeptor positiv/Her2 negativ), zur perioperativen Therapie des Harnblasenkarzinoms, für rezidivierende/refraktäre Her2-positive solide Tumore und das rezidivierende/refraktäre follikuläre Lymphom. Für diese Indikationen hat der CHMP (Committee for Medicinal Products for Human Use der EMA) in seiner Mai-Sitzung insgesamt 8 Zulassungserweiterungen und 1 Neuzulassung (Camizestrant) für erwachsene Patienten ausgesprochen. Ab sofort finden Sie die entsprechenden Therapieprotokolle in der Dacy-Knowledgebase.
| 5-FU/Folinsäure/Oxaliplatin/Cetuximab/Encorafenib | Braftovi in combination with cetuximab and FOLFOX is indicated for the first line treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation. |
| 5-FU/Folinsäure/Oxaliplatin/Cetuximab/Encorafenib | Erbitux is indicated for the treatment of adult patients with BRAF V600E mutant metastatic colorectal cancer in combination with encorafenib and FOLFOX for the first line treatment. |
| Carboplatin-AUC5/nab-Paclitaxel-100/Serplulimab-4.5 | Hetronifly in combination with carboplatin and nab-paclitaxel is indicated for the first-line treatment of adult patients with unresectable, locally advanced or metastatic squamous non-small cell lung carcinoma |
| CDK4/6-Inhibitor/Camizestrant | Etcamah in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) is indicated for the treatment of adult patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1‑mutation and without disease progression during first-line endocrine therapy in combination with a CDK4/6 inhibitor |
| Lenalidomid/Rituximab/Epcoritamab | Tepkinly in combination with lenalidomide and rituximab is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). |
| Pembrolizumab/Enfortumab-vedotin | Padcev, in combination with pembrolizumab, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment, is indicated for the treatment of adult patients with resectable muscle invasive bladder cancer (MIBC) who are ineligible for cisplatin-containing chemotherapy. |
| Sacituzumab Govitecan | Trodelvy is indicated as monotherapy for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and who are not candidates for PD-1 or PD-L1 inhibitor therapy. |
| Trastuzumab Deruxtecan | Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumours who have received prior treatment and who have no satisfactory treatment options |
Für die oben angegebenen Protokolle finden Sie weitere Informationen, wie z.B. die Protokollbeschreibungen, Fachinformationen oder Studienergebnisse in unserer Dokumentationssoftware Dacy oder im Fall des Plattenepithelkarzinoms der Lunge auch im Lungenkarzinom-Modul auf dieser Website unter dem Therapieprinzip BC 1L Platin/Taxan/PD-L1-AK für das Protokoll Carboplatin-AUC5/nab-Paclitaxel-100/Serplulimab-4.5.
